List view / Grid view
The new license agreement will support development of a potential…
The new license agreement will support development of a potential additional treatment option for patients at risk of atherosclerosis.
The next-generation B-cell depletion biologic therapy has demonstrated promise in…
The next-generation B-cell depletion biologic therapy has demonstrated promise in B-cell malignancies and autoimmune diseases.
A novel late-phase clinical candidate for diabetic macular edema and…
A novel late-phase clinical candidate for diabetic macular edema and neovascular age-related macular degeneration will be developed as part of the proposed agreement.
Following Phase I results, Merck will discontinue its development of…
Following Phase I results, Merck will discontinue its development of V590 and V591, two COVID-19 vaccine candidates.
